Genentech, Inc.
NEWS
The approval was based on interim analysis from the company’s Phase III IMpower110 trial.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
Genentech, a Roche company, announced positive results from the Phase II CITYSCAPE clinical trial in PD-L1-positive metastatic non-small cell lung cancer.
Pharma veteran Michael Varney, Genentech’s head of Research and Development, will retire from the company at the end of July after spending 15 years with the company.
Genentech, a Roche company, presented one-year data from FIREFISH Part 2, its pivotal trial of risdiplam in infants one to seven months old with symptomatic Type 1 spinal muscular atrophy.
The FDA recently approved the combination of Imbruvica-Rituximab for treating chronic lymphocytic leukemia. Here’s everything you need to know.
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
The NDA is for a new formulation of the drug as one-dose granules for oral suspension, would which largely be aimed at children and people who have difficulty swallowing.
JOBS
IN THE PRESS